Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 10/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.60 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.60 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.58 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20061358 | 0.90 | PIK3CD (0.65) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL20061360 | 0.87 | PIK3CD (0.60) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL20061363 | 0.85 | PIK3CD (0.53) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL20061438 | 0.83 | PIK3CD (0.57) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL20061435 | 0.81 | PIK3CD (0.62) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL20061448 | 0.80 | PIK3CD (0.51) | PIK3CGPIK3CD | |
| SCHEMBL20061370 | 0.80 | PIK3CD (0.62) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL20061417 | 0.79 | PIK3CD (0.63) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL356437 | 0.79 | PIK3CG (0.65) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 | |
| SCHEMBL20061365 | 0.78 | PIK3CG (0.64) | PIK3CGPIK3CAPIK3CBPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | WEE2, WEE1, ITK | PIK3CG 19/4885PIK3CA 18/4885PIK3CB 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.